AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine Cancer

NCT07712094 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

56

Enrollment

OTHER

Sponsor class

Conditions

Neuroendocrine Cancer

Interventions

DRUG: AK112
DRUG: Irinotecan
DRUG: Cisplatin
PROCEDURE: TACE

Sponsor

Tianjin Medical University Cancer Institute and Hospital